- 全部删除
- 您的购物车当前为空
Tunlametinib是高选择性口服MEK1/MEK2激酶抑制剂(对MEK1的IC50为1.9 nM),通过阻断RAS-RAF-MEK-ERK致癌信号通路诱导肿瘤细胞周期阻滞与凋亡。对BRAF V600E或KRAS G12C等突变型肿瘤细胞具有强抑制活性,与BRAF/KRASG12C/SHP2抑制剂及多西他赛(Docetaxel)联用呈现协同效应,目前已应用于黑色素瘤、结直肠癌及非小细胞肺癌等RAS/RAF驱动型肿瘤的靶向治疗。
Tunlametinib是高选择性口服MEK1/MEK2激酶抑制剂(对MEK1的IC50为1.9 nM),通过阻断RAS-RAF-MEK-ERK致癌信号通路诱导肿瘤细胞周期阻滞与凋亡。对BRAF V600E或KRAS G12C等突变型肿瘤细胞具有强抑制活性,与BRAF/KRASG12C/SHP2抑制剂及多西他赛(Docetaxel)联用呈现协同效应,目前已应用于黑色素瘤、结直肠癌及非小细胞肺癌等RAS/RAF驱动型肿瘤的靶向治疗。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 346 | In stock | |
5 mg | ¥ 823 | In stock | |
10 mg | ¥ 1,290 | In stock | |
1 mL x 10 mM (in DMSO) | ¥ 888 | In stock |
Tunlametinib 相关产品
产品描述 | Tunlametinib is a highly selective, orally bioavailable small molecule inhibitor of MEK1 and MEK2 kinases with a reported IC50 value of 1.9 nM for MEK1. Tunlametinib exerts its antitumor effects by blocking the oncogenic RAS-RAF-MEK-ERK signaling pathway, thereby inducing tumor cell cycle arrest and promoting apoptosis, Tunlametinib demonstrates strong inhibitory activity against various RAS/RAF-mutant cancer cells such as those harboring BRAF V600E or KRAS G12C mutations, shows synergistic effects in combination with BRAF/KRASG12C/SHP2 inhibitors and Docetaxel, and is used in targeted therapy for RAS/RAF-driven cancers including melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC). |
靶点活性 | HT-291 cells:10.07 nM, Colo-829 cells:3.46 nM, A375 cells:0.86 nM, COLO 205 cells:0.94 nM, HL-60 cells:0.67 nM, A549 cells:59.89 nM |
体外活性 | 方法:Tunlametinib (1-9 nM,48 h) 处理 A375 细胞,评估对细胞周期的影响。 |
体内活性 | 方法:Tunlametinib (1、3、6 mg/kg,口服,每日 1 次,21 天) 处理 |
别名 | 妥拉美替尼, HL-085, HL085 |
分子量 | 491.25 |
分子式 | C16H12F2IN3O3S |
CAS No. | 1801756-06-8 |
Smiles | O=C(NOCCO)C1=CC=2SC=NC2C(F)=C1NC3=CC=C(I)C=C3F |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 80 mg/mL (162.85 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容